{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T23:25:27Z","timestamp":1778801127300,"version":"3.51.4"},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["tcmonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cardiovascular Medicine"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.tcm.2014.10.015","type":"journal-article","created":{"date-parts":[[2014,10,28]],"date-time":"2014-10-28T01:40:56Z","timestamp":1414460456000},"page":"340-347","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["2013 ACC\/AHA cholesterol treatment guideline: Paradigm shifts in managing atherosclerotic cardiovascular disease risk"],"prefix":"10.1016","volume":"25","author":[{"given":"Jonathan B.","family":"Finkel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"25 Pt B","key":"10.1016\/j.tcm.2014.10.015_bib1","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a Report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.tcm.2014.10.015_bib2","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)","volume":"285","author":"Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults","year":"2001","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.tcm.2014.10.015_bib3","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1016\/j.jacc.2014.02.578","article-title":"2013 ACC\/AHA cholesterol treatment guideline: what was done well and what could be done better","volume":"63","author":"Martin","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.tcm.2014.10.015_bib4","doi-asserted-by":"crossref","first-page":"356","DOI":"10.7326\/M13-2805","article-title":"Concepts and controversies: the 2013 American College of Cardiology\/American Heart Association risk assessment and cholesterol treatment guidelines","volume":"160","author":"Martin","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.tcm.2014.10.015_bib5","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/S0140-6736(13)62388-0","article-title":"Statins: new American guidelines for prevention of cardiovascular disease","volume":"382","author":"Ridker","year":"2013","journal-title":"Lancet"},{"issue":"25 Pt B","key":"10.1016\/j.tcm.2014.10.015_bib6","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1016\/j.jacc.2013.11.003","article-title":"2013 AHA\/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Eckel","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"25 Pt B","key":"10.1016\/j.tcm.2014.10.015_bib7","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1016\/j.jacc.2013.11.005","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Goff","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.tcm.2014.10.015_bib8","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.tcm.2014.10.015_bib9","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.cjca.2012.11.032","article-title":"2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult","volume":"29","author":"Anderson","year":"2013","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.tcm.2014.10.015_bib10","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.jacl.2013.10.001","article-title":"An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia","volume":"7","author":"Grundy","year":"2013","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.tcm.2014.10.015_bib11","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1161\/CIRCRESAHA.114.303398","article-title":"The 2013 ACC\/AHA guidelines on the treatment of blood cholesterol: questions, questions, questions","volume":"114","author":"Ginsberg","year":"2014","journal-title":"Circ Res"},{"issue":"2","key":"10.1016\/j.tcm.2014.10.015_bib12","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"issue":"9753","key":"10.1016\/j.tcm.2014.10.015_bib13","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.tcm.2014.10.015_bib14","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.tcm.2014.10.015_bib15","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2014.10.015_bib16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.mcna.2012.01.009","article-title":"LDL cholesterol: the lower the better","volume":"96","author":"Martin","year":"2012","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.tcm.2014.10.015_bib17","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","article-title":"Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials","volume":"64","author":"Boekholdt","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.tcm.2014.10.015_bib18","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2014.10.015_bib19","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2014.10.015_bib20","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1161\/CIR.0b013e31820faaf8","article-title":"Effectiveness-based guidelines for the prevention of cardiovascular disease in women\u20142011 update: a guideline from the american heart association","volume":"123","author":"Mosca","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2014.10.015_bib21","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1001\/jama.2014.2630","article-title":"Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations","volume":"311","author":"Muntner","year":"2014","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.tcm.2014.10.015_bib22","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1161\/CIRCULATIONAHA.113.007648","article-title":"Comment on the reports of over-estimation of ASCVD risk using the 2013 AHA\/ACC risk equation","volume":"129","author":"Muntner","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2014.10.015_bib23","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","article-title":"General cardiovascular risk profile for use in primary care: the Framingham Heart Study","volume":"117","author":"D\u05f3Agostino","year":"2008","journal-title":"Circulation"},{"issue":"25 PA","key":"10.1016\/j.tcm.2014.10.015_bib24","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/j.jacc.2014.04.009","article-title":"Curing atherosclerosis should be the next major cardiovascular prevention goal","volume":"63","author":"Robinson","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.tcm.2014.10.015_bib25","first-page":"758","article-title":"Perspective on the 2013 American Heart Association\/American College of Cardiology guideline for the use of statins in primary prevention of low-risk individuals","volume":"114","author":"Breslow","year":"2014"},{"key":"10.1016\/j.tcm.2014.10.015_bib26","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jacl.2014.07.007","article-title":"National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1\u2014executive summary","volume":"8","author":"Jacobson","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.tcm.2014.10.015_bib27","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.jacc.2013.07.056","article-title":"Targeting the proprotein convertase subtilisin\/kexin type 9 for the treatment of dyslipidemia and atherosclerosis","volume":"62","author":"Urban","year":"2013","journal-title":"J Am Coll Cardiol"}],"container-title":["Trends in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1050173814001911?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1050173814001911?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T05:51:14Z","timestamp":1538113874000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1050173814001911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S1050173814001911"],"URL":"https:\/\/doi.org\/10.1016\/j.tcm.2014.10.015","relation":{},"ISSN":["1050-1738"],"issn-type":[{"value":"1050-1738","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"2013 ACC\/AHA cholesterol treatment guideline: Paradigm shifts in managing atherosclerotic cardiovascular disease risk","name":"articletitle","label":"Article Title"},{"value":"Trends in Cardiovascular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tcm.2014.10.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}